James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Before Freaking Out Over June’s Retail Sales Lull …

Last month's retail sales tumbled, but any alarm spurred by the data overlooks a very important detail about the calendar.

Will Intel Stock Look Even Better After Q2 Earnings?

Intel stock has been roughed up all year long, and for good reason. The pros, however, are mixed as to whether the worst is over.

What BAC Owners Need to Know Before Wednesday’s Earnings Report

BAC stock has been choppy and unproductive in the shadow of equally choppy and unimpressive earnings. That, however, may be about to change.

8 Biotech Stocks to Buy

Biotech stocks broadly feel overbought, but the sector still has plenty of stocks to buy that aren't past their prime.

Why Ascena Retail Group Inc. (ASNA), Corning Incorporated (GLW) and Horizon Pharma PLC (HZNP) Are 3 of Today’s Worst Stocks

Ascena Retail Group (ASNA), Corning (GLW) and Horizon Pharma (HZNP) would like to take a mulligan after today's miserable results.